PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi

Vaccine

Volumn 32, Issue 44, 2014, Pages 5801-5808

  Njuguna, Irene N ^a   Ambler, Gwen ^b   Reilly, Marie ^c   Ondondo, Beatrice ^d   Kanyugo, Mercy ^a   Lohman Payne, Barbara ^a   Gichuhi, Christine ^a   Borthwick, Nicola ^d   Black, Antony ^d   Mehedi, Shams Rony ^e   Sun, Jiyu ^c   Maleche Obimbo, Elizabeth ^a   Chohan, Bhavna ^a   John Stewart, Grace C ^b   Jaoko, Walter ^a   Hanke, Tomáš ^d,f  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Medical Research Council Unit   (Gambia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

EPI vaccines; Exposed uninfected infants; HIV 1; Infant vaccine trial in Africa; KEPI vaccines; Modified vaccinia virus Ankara (MVA); Pediatric HIV 1 vaccines

Indexed keywords

COTRIMOXAZOLE; CREATININE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MODIFIED VACCINIA VIRUS ANKARA HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IFNG PROTEIN, HUMAN; MVA-HIVA VACCINE;

ABSCESS; ANEMIA; ARTICLE; BIRTH WEIGHT; CELLULAR IMMUNITY; COLIC; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ECZEMA; FEMALE; GASTROENTERITIS; GESTATIONAL AGE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INFANT; INFANT FEEDING; INFECTION PREVENTION; KENYA; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; NEUTROPENIA; OTITIS MEDIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTICEMIA; SKIN REDNESS; SKULL FRACTURE; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VERTICAL TRANSMISSION; ADULT; BLOOD; CLINICAL TRIAL; HIV INFECTIONS; IMMUNOLOGY; MOTHER; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; T LYMPHOCYTE; YOUNG ADULT;

ADULT; AIDS VACCINES; ANTI-HIV AGENTS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; KENYA; MALE; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84908073705     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.034     Document Type: Article

References (49)

1. Bae W.H., Wester C., Smeaton L.M., Shapiro R.L., Lockman S., Onyait K., et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 2008, 22:1633-1640.
2. Chappuy H., Treluyer J.M., Jullien V., Dimet J., Rey E., Fouche M., et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004, 48:4332-4336.
3. Chappuy H., Treluyer J.M., Rey E., Dimet J., Fouche M., Firtion G., et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004, 191:558-562.
4. Feiterna-Sperling C., Weizsaecker K., Buhrer C., Casteleyn S., Loui A., Schmitz T., et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007, 45:43-51.
5. Njuguna I., Reilly M., Jaoko W., Gichuhi C., Ambler G., Maleche-Obimbo E., et al. Infant neutrapenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of HIV. Retrovirology 2014, 6:1-5.
6. Pacheco S.E., McIntosh K., Lu M., Mofenson L.M., Diaz C., Foca M., et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006, 194:1089-1097.
7. Shapiro R.L., Holland D.T., Capparelli E., Lockman S., Thior I., Wester C., et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005, 192:720-727.
8. Six Week Extended-Dose Nevirapine Study, Bedri T.A., Gudetta B., Isehak A., Kumbi S., Lulseged S., et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008, 372:300-313.
9. Richardson B.A., Mbori-Ngacha D., Lavreys L., John-Stewart G.C., Nduati R., Panteleeff D.D., et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 2003, 77:7120-7123.
10. Mo H., Monard S., Pollack H., Ip J., Rochford G., Wu L., et al. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses 1998, 14:607-617.
11. Luzuriaga K., Sullivan J.L. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev 2002, 4:21-26.
12. Farber D.L., Yudanin N.A., Restifo N.P. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014, 14:24-35.
13. Cunningham C.K., McFarland E. Vaccines for prevention of mother-to-child transmission of HIV. Curr Opin HIV AIDS 2008, 3:151-154.
14. Gomez C.E., Perdiguero B., Garcia-Arriaza J., Esteban M. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 2013, 12:1395-1416.
15. Hanke T., Goonetilleke N., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol 2007, 88:1-12.
16. Hanke T., McMichael A.J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000, 6:951-955.
17. Borkowsky W., Wara D., Fenton T., McNamara J., Kang M., Mofenson L., et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 2000, 181:890-896.
18. Cunningham C.K., Wara D.W., Kang M., Fenton T., Hawkins E., McNamara J., et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 2001, 32:801-807.
19. McFarland E.J., Borkowsky W., Fenton T., Wara D., McNamara J., Samson P., et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 2001, 184:1331-1335.
20. Johnson D.C., McFarland E.J., Muresan P., Fenton T., McNamara J., Read J.S., et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 2005, 192:2129-2133.
21. McFarland E.J., Johnson D.C., Muresan P., Fenton T., Tomaras G.D., McNamara J., et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006, 20:1481-1489.
22. Kintu K., Andrew P., Musoke P., Richardson P., Asiimwe-Kateera B., Nakyanzi T., et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 2013, 63:1-8.
23. Afolabi M.O., Ndure J., Drammeh A., Darboe F., Mehedi S.-R., Rowland-Jones S.L., et al. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One 2013, 8:e78289.
24. van Gageldonk P.G., van Schaijk F.G., van der Klis F.R., Berbers G.A. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008, 335:79-89.
25. Eggers M., Terletskaia-Ladwig E., Rabenau H.F., Doerr H.W., Diedrich S., Enders G., et al. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany. BMC Infect Dis 2010, 10:347.
26. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J., et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011, 3:88ra56.
27. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Mauff K., et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011, 203:1832-1843.
28. Hanke T. Conserved immunogens in prime-bost strategies for te next-generation HIV-1 vaccines. Expert Opin Biol Ther 2014, 14:601-616.
29. + T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 2011, 41:3542-3552.
30. Hopkins R., Bridgeman A., Joseph J., Gilbert S.C., McShane H., Hanke T. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 2011, 6:e20067.
31. Im E.J., Saubi N., Virgili G., Sander C., Teoh D., Gatell J.M., et al. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 2007, 81:9408-9418.
32. Rosario M., Fulkerson J., Soneji S., Parker J., Im E.J., Borthwick N., et al. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 2010, 84:7815-7821.
33. Rosario M., Hopkins R., Fulkerson J., Borthwick N., Quigley M.F., Joseph J., et al. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 2010, 84:5898-5908.
34. Saubi N., Gea-Mallorqui E., Ferrer P., Hurtado C., Sanchez-Ubeda S., Eto Y., et al. Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. Mol Ther Methods Clin Dev 2014, 1:14017.
35. Saubi N., Im E.J., Fernandez-Lloris R., Gil O., Cardona P.J., Gatell J.M., et al. Newborn mice vaccination with BCG.HIVA+MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol 2011, 2011:516219.
36. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U., et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014, 22:464-475.
37. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
38. Sheehy S.H., Duncan C.J., Elias S.C., Choudhary P., Biswas S., Halstead F.D., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2013, 20:2355-2368.
39. Letourneau S., Im E.-J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2:e984.
40. McMichael A.J., Haynes B.F. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012, 13:423-427.
41. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
42. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
43. Clerici M., Saresella M., Colombo F., Fossati S., Sala N., Bricalli D., et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000, 96:3866-3871.
44. Kidzeru E.B., Hesseling A.C., Passmore J.A., Myer L., Gamieldien H., Tchakoute C.T., et al. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. AIDS 2014.
45. + T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents. J Trop Pediatr 2010, 56:427-432.
46. Nielsen S.D., Jeppesen D.L., Kolte L., Clark D.R., Sorensen T.U., Dreves A.M., et al. Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood 2001, 98:398-404.
47. Jones S.A., Groome M., Koen A., Van Niekerk N., Sewraj P., Kuwanda L., et al. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One 2013, 8:e72794.
48. Abramczuk B.M., Mazzola T.N., Moreno Y.M., Zorzeto T.Q., Quintilio W., Wolf P.S., et al. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol 2011, 18:1406-1409.
49. Thaithumyanon P., Punnahitananda S., Praisuwanna P., Thisyakorn U., Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai 2002, 85:277-282.